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Abstract
The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant
proportion of the incretin effect during the postprandial period and the
subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes
(T2D) led to new therapeutic strategies being developed for T2D treatment
based on GLP-1 action. Although owing to its short half-life exogenous
GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much
longer half-life than native GLP-1, have proven to be effective for T2D
treatment since they prolong the incretin effect in patients. These GLP-1
mimetics are a desirable therapeutic option for T2D since they do not
provoke hypoglycaemia or weight gain and have simple modes of
administration and monitoring. Additionally, over more recent years, GLP-1
action has been found to mediate systemic physiological beneficial effects
and this has high clinical relevance due to the post-diagnosis complications
of T2D. Indeed, recent studies have found that certain GLP-1 analogue
therapies improve the cardiovascular outcomes for people with diabetes.
Furthermore, GLP-1–based therapies may enable new therapeutic
strategies for diseases that can also arise independently of the clinical
manifestation of T2D, such as dementia and Parkinson’s disease. GLP-1
functions by binding to its receptor (GLP-1R), which expresses mainly in
pancreatic islet beta cells. A better understanding of the mechanisms and
signalling pathways by which acute and chronic GLP-1R activation
alleviates disease phenotypes and induces desirable physiological
responses during healthy conditions will likely lead to the development of
new therapeutic GLP-1 mimetic–based therapies, which improve prognosis
to a greater extent than current therapies for an array of diseases.
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Introduction
Glucagon-like peptide 1 (GLP-1) was initially identified as a 
gut-derived incretin hormone that augments insulin secretion 
in a glucose-dependent manner from pancreatic islet beta cells 
during the postprandial period1,2. Subsequent research discov-
ered that GLP-1 also lowered glycaemia by inhibiting glucagon 
secretion from pancreatic alpha cells, delaying gastric empty-
ing and mediating induction of satiety1–4. Thus, GLP-1 maintains 
metabolic homeostasis during the postprandial period via mul-
tiple actions. For over a decade now, GLP-1 receptor agonists, 
which have a much longer half-life than endogenous GLP-1, 
have been an effective treatment option for type 2 diabetes 
(T2D)5,6. Interestingly, studies over more recent years have also 
identified that GLP-1 has beneficial physiological effects on 
a variety of tissues such as the cardiovascular and neurologi-
cal systems and this has high clinical relevance given the multi-
ple and common post-diagnosis complications associated with 
T2D1,2,5,7–10. GLP-1 mediates its effects by binding to its recep-
tor, the GLP-1 receptor (GLP-1R), which is a G protein–coupled 
receptor that is abundantly present in the pancreatic beta cells, 
gut, and the central nervous system (CNS) and moderately in 
the lung, heart, kidney, blood vessels, pancreatic alpha cells, 
and peripheral nervous system2,4,7. However, studies have 
reported that GLP-1 exerts its effects on certain extrapancreatic 
tissues despite the absence of GLP-1R, which implies that this 
hormone may also act via currently unidentified receptors or 
mechanisms2,7. Therefore, given the continual emerging evidence, 
it has become accepted that GLP-1 has systemic physiological 
effects and that the actions of this hormone are not limited to 
mediating the incretin effect, although this is still widely accepted 
to be GLP-1’s most important and clinically relevant role to 
date2,7,11,12. Given these observations, GLP-1–based therapies 
may also provide new strategies for diseases that can arise 
independently of T2D in tissues susceptible to GLP-1 action7,11,13. 
This review aims to summarise the well-established and 
speculative physiological roles of GLP-1 and highlight what 
studies have found over recent years in different tissues with 
regard to the physiological responses induced by endogenous 
GLP-1 and GLP-1R agonists (used for therapeutic purposes) 
and discuss the future implications and clinical relevance of 
these findings.
GLP-1 and its mimetics: physiological roles, therapeutic 
uses and recent developments
Given the prevalence and incidence of T2D and the disease- 
associated post-diagnosis complications such as cardiovascular 
disease (CVD), and the observation that GLP-1 activity is 
retained in T2D whereas gastric inhibitory polypeptide (GIP) 
activity is greatly reduced, research was conducted to develop a 
new therapeutic strategy for T2D treatment using GLP-1–based 
therapies8–10,14. Initially, success was limited, as endogenous GLP-1 
and many of its early analogues have very short half-lives due 
to rapid inactivation by dipeptidyl peptidase 4 (DPP-4) in the 
circulation, requiring continuous treatment to maintain therapeu-
tic levels, which was not practical6,7,15. However, GLP-1 analogues 
were developed that had much greater half-life than endogenous 
GLP-1 whilst retaining the bioactivity12,16. GLP-1R agonists used 
in T2D treatment are either derivatives of native GLP-1 (liraglutide, 
albiglutide, semaglutide and dulaglutide), which have been 
modified to be resistant to DPP-4 inactivation, or derivatives 
of exendin-4 (exenatide, lixisenatide and exenatide-LR)4,17. 
Exendin-4, which shares 53% homology with human GLP-1, was 
originally isolated from the saliva of the Gila monster lizard and is 
resistant to the action of DPP-44. Key pharmacological and clinical 
features of clinically available GLP-1R agonists are presented in 
Table 1.
These agonists were found to effectively reduce hyperglycae-
mia in subjects with diabetes by prolonging the incretin effect 
and have proven to be a welcome addition to the therapeutic 
armamentarium in patients where insulin therapy was deemed 
as the next step after the failure of oral hypoglycaemic agents. 
Table 1. Current glucagon-like peptide 1 receptor (GLP-1R) agonists used in 
type 2 diabetes therapy.
GLP-1R agonist generic 
name (trade name)
Dosing Half-life Administration 
required 
before meals?
Short-acting
Exenatide (Byetta) Twice daily 2.4hours Yes
Lixisenatide (Lyxumia) Once daily 4hours Yes
Intermediate-acting
Liraglutide (Victoza) Once daily 12hours No
Long-acting
Exenatide-LAR (Bydureon) Once weekly 96hours No
Albiglutide (Tanzeum)a Once weekly 6–8 days No
Dulaglutide (Trulicity) Once weekly 90hours No
Semaglutide (Ozempic) Once weekly 165–184hours No
Information in this table is taken from 4,16,17.
a This product was globally withdrawn in July 2018 for commercial reasons.
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GLP-1R agonist therapies have low rates of hypoglycaemia 
and are also associated with weight loss and not weight gain 
(with current dosages used in therapies), which is an undesirable 
side effect of some other glucose-lowering therapies4,6. The 
availability of various GLP-1R agonists with differing pharma-
cokinetic profiles enables individualised treatment options for 
T2D management, which has clinical relevance given patients’ 
differing routines, glycaemic control and diets4. Furthermore, 
T2D is a highly multifactorial disease and pathology arises in 
multiple organs8,9,14. Many of these organs express GLP-1R, 
which gives GLP-1 analogue therapies the potential to alleviate 
the diabetic phenotype systemically and the potential to provide 
new treatments for other diseases such as dementia and CVD in 
non-diabetic individuals2,7.
In the 1960s, it was shown that orally administered glucose 
induces a much larger insulin response than that induced by 
intravenously administered glucose, despite the similar resulting 
plasma glucose levels: the incretin effect18. Subsequently, it was 
identified that two hormones (GIP and GLP-1) released by the 
gastrointestinal tract (GIT) mediate the incretin effect2,7,19. In 
response to postprandial nutrient loads, enteroendocrine L cells 
from the intestine secrete GLP-11,2. It has been established that 
there is a direct correlation between the levels of nutrients exposed 
to L cells and the levels of GLP-1 in circulation20. Initially, 
GLP-1 secretion by L cells was postulated to be dependent on 
postprandial glucose loads20,21. However, ingestion of mixed 
nutrients (carbohydrates, fats and proteins) was shown to result 
in greater GLP-1 secretion in comparison with just glucose 
ingestion21. It has also been demonstrated that fats and proteins, like 
glucose, can independently induce GLP-1 secretion20. The levels 
of GLP-1 in fasting plasma are about 5 to 15 pM, which increases 
to 40 to 60 pM during the postprandial period22,23. L cells initiate 
the GLP-1 response within 15 minutes after food ingestion, and 
GLP-1 levels peak in the circulation after about 30 minutes20,24,25. 
It is still unclear how the GLP-1 response is generated so rapidly 
but it has been suggested that the vagal nerve and L cells in the 
upper jejunum part of the small intestine may be involved1. 
However, the response is generated after the ‘cephalic phase’ of 
insulin secretion, implying that neuronal signals that promote 
insulin release do not influence GLP-1 release1,23. Rodent studies 
have demonstrated that, upon GIP stimulation, the nervous system 
promotes GLP-1 secretion from L cells, which express the recep-
tors involved in neuronal signalling26,27. However, in chloralose- 
anaesthetised pigs, electrical stimulation of the vagal trunks at 
the level of the diaphragm had no effect on GLP-1 secretion, and 
human cephalic phase studies and studies in vagotomised humans 
found similar results28–30. Figure 1 summarises the processes in 
L cells that are known to lead to or that may lead to GLP-1 
secretion.
Studies have revealed that the role of GLP-1 release from L cells 
is not limited to initiating the desired physiological response to 
ingested glucose but also proteins and lipids (for example, reducing 
triglyceride excursions), giving GLP-1 a more diverse role in 
maintaining metabolic homeostasis during the postprandial 
period2,20,21. Additionally, understanding the neuronal regulation 
of GLP-1 release in humans is unclear, as is how other 
hormones involved in metabolic homeostasis regulate L-cell 
GLP-1 secretion26,27.
GLP-1 has a very short half-life (1–2 minutes) in the 
circulation1 because of its rapid inactivation by proteolytic 
actions of  DPP-41,7. Consequently, it has been become generally 
accepted that about 85% of GLP-1 exists in the inactive form in 
circulation23. Since the majority of GLP-1 is inactivated rapidly 
after secretion, its response is highly inefficient with regard to 
ATP expenditure (GLP-1 synthesis requires ATP)2,23. It has become 
generally accepted that endogenous GLP-1 activates sensory 
afferents of the enteric nervous system, which helps to promote 
the desired postprandial response, in addition to mediating the 
incretin effect via the endocrine route to islet beta cells1,2,31,32. 
Although it is still unclear why the GLP-1 response is so wasteful 
from a bioenergetics perspective, recent studies have suggested 
that the inactive GLP-1 has actions on the liver, vasculature 
and heart which are comparable to those of insulin33. However, 
the notion that GLP-1 has any action on the liver is an area of 
controversy, given the absence of GLP-1R in hepatocytes2. 
Therefore, it is possible that the ‘inactive forms’ are not actually 
inactive and act on currently unidentified signalling pathways 
and this seems likely to be the case as it is very unlikely that 
evolution has developed such an ATP-wasteful response. 
However, GLP-1R agonists (such as liraglutide and exenatide) 
that are used in T2D therapy are all synthetically developed. In 
contrast to endogenous GLP-1, they have a half-life of several 
hours or more as they are resistant to DPP-4 inactivation4,34. This 
results in prolonged pancreatic beta-cell GLP-1R activation that 
in turn prolongs the incretin effect, resulting in a reduction of 
hyperglycaemia in most patients4,35.
The incretin hormones play a crucial role in maintaining metabolic 
homeostasis since about 60 to 70% of the total postprandial 
insulin released into circulation is due to the action of these 
hormones2,36. GIP and GLP-1 account for about 60% and 40% of 
the incretin effect, respectively2. The action of GLP-1 is dependent 
on blood glucose levels since it can only potentiate glucose- 
stimulated insulin secretion from islet beta cells7. Furthermore, 
GLP-1 suppresses glucagon secretion from islet alpha cells, but 
only when glucose levels are above fasting, which assists in the 
ability of postprandial insulin to mediate anabolism of ingested 
nutrients1,2,7. Given the importance of the correct balance of insulin 
and glucagon activity being maintained to mediate desired net 
systemic anabolic or catabolic metabolic effects in response to 
nutrient supply and demand, GLP-1 activity plays a critical role in 
maintaining metabolic homeostasis during the postprandial period 
via insulinotropic and glucagonostatic effects2,4. Activation of 
GLP-1R results in a rapid (seconds to minutes) potentiation of 
insulin secretion from islet beta cells which is achieved via rapid 
cAMP production, which results in the activation of protein kinase 
A (PKA) and exchange protein directly activated by cAMP (Epac), 
and these two effectors modify several targets in the secretory 
machinery, resulting in enhanced insulin secretion2,12. Additionally, 
GLP-1R activation results in transcription of genes involved 
in proliferation, neogenesis and apoptotic resistance in islet 
beta cells, expanding GLP-1’s role from potentiating insulin 
secretion from islet beta cells to promoting their survival via 
translocation of pancreatic duodenal homeobox 1 (PDX-1) 
transcription factor to the nucleus2,12,42. Chronic liraglutide 
treatment in diabetic mice was shown to prevent loss of beta-cell 
mass, by increasing the proliferation of beta cells and decreasing 
beta-cell apoptosis, after alloxan injection35. Inhibition of beta-cell 
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Figure 1. Summary of L-cell processes that are known to lead to or that may lead to glucagon-like peptide 1 (GLP-1) secretion into 
the circulation. Sodium entry into the L cell promotes calcium influx by inducing depolarisation, and glucose also induces calcium influx 
by raising ATP levels as a result of its catabolism. The binding of fatty acids to specific receptors also raises intracellular calcium levels. The 
now-elevated calcium levels promote exocytosis of GLP-1–containing vesicles, releasing GLP-1 into the circulation. Proteins also promote 
GLP-1 release, but it is not currently mechanistically understood how. L cells have been shown to express receptors for metabolic hormones, 
including insulin, leptin and gastric inhibitory polypeptide (GIP). The degree to which leptin and insulin stimulate overall GLP-1 secretion is 
still unclear, but GIP-mediated GLP-1 release has been shown to occur in rodents via acetylcholine release by the enteric nervous system. 
Supraphysiological concentrations of GIP potentially activate GIP receptors on L cells, potentially enhancing GLP-1 secretion. This figure and 
information in its legend are adapted from26,37–41.
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apoptosis in isolated human pancreatic beta cells was also reported 
after liraglutide administration, and the beta-cell proliferation rate 
was increased up to threefold after incubation for 24 hours43. In 
both animal and human studies, GLP-1/exendin-4 has also been 
shown to increase the beta-cell mass44. Endogenous GLP-1 not 
only protects against apoptosis but also induces proliferation of 
rat primary islet cells and beta-cell lines12,45. GLP-1R activation 
has also been proposed to reduce lipotoxicity, glucotoxicity, Ca2+ 
depletion, excess nitric oxide, cytokine-induced endoplasmic 
reticulum (ER) stress and oxidative stress in both primary beta cells 
and cell lines via multiple downstream signalling pathways46–50. 
One study found that GLP-1R signalling alters the intracellular 
response from the translational repression to the translational 
recovery phase in a PKA-dependent manner46. GLP-1 has recently 
been shown to regulate autophagy in beta cells51,52. Exendin-4 treat-
ment was shown to facilitate autophagy in rat INS-1E cells and 
isolated human islets under chronic exposure to excess nutrients 
by preventing autophagosomal-lysosomal fusion impairment. Its 
treatment was also reported to increase lysosomal function, which 
improved autophagosome clearance and thereby reduced islet 
beta-cell injury in a rat model of tacrolimus-induced diabetes53. 
Additionally, exendin-4 treatment in vivo has been shown to 
decrease tacrolimus-induced oxidative stress, hyperglycemia, 
and apoptosis [43]. Interestingly, recent studies have found that 
chronic GLP-1R activation results in metabolic reprogramming 
associated with upregulation of glycolytic enzymes and increased 
ATP production54. It has been postulated that an enhancement 
in metabolism by GLP-1 treatment likely decreases ER stress 
by increasing intracellular Ca2+ and mitochondrial ATP levels, 
which then are used in the maintenance of ER homeostasis12. 
Interestingly, chronic GLP-1R activation also results in the 
activation of distinct signalling pathways; for instance, GLP-1R 
agonists have been reported to promote the secretion of insulin-
like growth factor 2 and induce expression of its receptor, which 
is thought to contribute to the pro-survival abilities of GLP-1 in 
islet beta cells12,55,56. Given that ER stress, impaired autophagy 
and proliferation, and increased apoptosis are all thought to 
contribute to islet beta-cell dysfunction in T2D, and the findings 
that GLP-1R activation can alleviate all of these, suggests 
GLP-1 and its analogues do more than just augmenting insulin 
secretion12. However, currently, there are no data from recent 
long-term clinical studies to suggest that GLP-1–based 
therapies exert protective effects on islet beta cells, and it is 
unclear whether the maximum insulin enhancement is achieved 
with present dosages used clinically, which are currently limited 
by side effects10,57–60. Figure 2 summarises the processes in islet 
beta cells that are influenced by postprandial glucose loads and 
GLP-1 action.
The regulation of alpha cells by GLP-1 remains an area of 
controversy2,7,61,62. However, it is firmly established that the ability 
of GLP-1 to inhibit glucagon secretion is not dependent on its 
insulinotropic effects, given that GLP-1 is able to lower fasting 
plasma glucose levels in people with type 1 diabetes7,63. 
Despite the low and controversial GLP-1R expression in islet 
alpha cells, recent studies have provided evidence that GLP-1R 
agonists mediate direct effects on alpha cells via the presence 
of GLP-1R7,61,62. Islet alpha-cell GLP-1R knockout mice failed to 
inhibit glucagon secretion at high glucose levels; interestingly, 
these mice had impaired glucagon secretion during low glu-
cose conditions62. Another recent study found that GLP-1 
action on human pancreatic islet alpha cells was not dependent 
on paracrine signalling since preventing insulin and somato-
statin signalling had no effect on the inhibition of glucagon 
secretion61. Until recently, there was a strong consensus in the 
literature that GLP-1 acts on alpha cells through an unidenti-
fied receptor or through paracrine mechanisms (or both) via 
insulin and somatostatin release from islet beta and delta cells, 
respectively2,7. Hyperglycaemia in T2D is now accepted to be 
induced by both hyperglucagonemia and hypoinsulinemia, 
and up to 50% of the excess plasma glucose levels in patients 
has been postulated to arise from inappropriate glucagon 
secretion64,65. Given that T2D is now considered to be a bihor-
monal disorder, how GLP-1R agonists influence glucagon 
secretion is of high clinical relevance7,66.
Studies have revealed that GLP-1 has multiple extrapancreatic 
targets and effects, which not only assists with inducing the 
desired physiological response during the postprandial period 
but also has beneficial effects on alleviating pathology associated 
with certain tissues and organs systemically, which arises 
because of T2D manifestation or independently of T2D2,8,9,12. 
These findings are of clinical importance since there is demand 
for new therapeutic strategies that both reduce the prevalence and 
incidence of T2D post-diagnosis complications and provide 
better prognosis than current treatments for diseases such as 
dementia2,7–9,12. Indeed, recent studies have found that certain 
GLP-1 analogue therapies confer cardiovascular benefits to 
people with diabetes, which has high clinical importance given 
the prevalence of the cardiovascular comorbidity of diabetes10. 
Owing to the weight loss achieved as a result of the ability 
of this drug to mediate satiety, liraglutide was also recently 
approved for the treatment of obesity in individuals without 
diabetes67. It was initially postulated that the effect of GLP-1 
on appetite could be due to its negative regulation of gut motil-
ity; however, evidence that GLP-1 has direct effects on specific 
neurons in the hypothalamus has emerged24. GLP-1 is expressed 
in neurons of the brainstem and GLP-1R is present in the 
hypothalamic areas that control energy homeostasis and food 
intake, including the arcuate nucleus, paraventricular nucleus, 
and dorsomedial nucleus1,68. Intracerebroventricular injection 
of GLP-1 inhibits food intake in rats and this activity is blocked 
by exendin9–39, demonstrating that GLP-1 has direct effects on 
neurons69,70. Studies have shown that intracerebroventricular 
administration of GLP-1 in humans induces satiety even in 
the absence of food in the GIT and when gastric emptying has 
been inhibited; thus, GLP-1 induces satiety via its direct 
effects on neurons in the caudal brainstem1,24,68. The mecha-
nism by which peripherally administered GLP-1 induces sati-
ety has yet to be elucidated, but it likely involves signals being 
generated by GLP-1 binding to GLP-1R on neurons in the GIT, 
hepatoportal bed and CNS1,71. The differences in weight loss 
reported for the various GLP-1 analogues currently used to treat 
T2D are likely related to their penetration of the CNS, allowing 
central GLP-1R binding72,73. Additionally, some studies have 
found evidence that GLP-1–based therapies alleviate pathology 
associated with other diseases such as dementia in non- 
diabetic individuals, although there is controversy about the 
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Figure 2. Summary of islet beta-cell processes that are influenced by postprandial glucose loads and glucagon-like peptide 1 
(GLP-1) action. When the plasma glucose rises, glucokinase initiates glucose catabolism, resulting in an increase in the cell’s ATP levels, 
which results in closure of ATP-sensitive potassium channels, causing membrane depolarisation and calcium influx. The resulting calcium 
influx triggers insulin secretion by promoting movement of insulin vesicles to the cell membrane. The binding of GLP-1 to GLP-1R enhances 
glucose-stimulated insulin secretion by initiating cAMP production via adenylyl cyclase activity that in turn activates protein kinase A (PKA) 
and exchange protein directly activated by cAMP (Epac). Activated PKA and Epac augment extracellular calcium influx induced by glucose 
catabolism via further promoting closure of potassium channels, and Epac also raises the intracellular calcium levels directly via promoting 
calcium release from the endoplasmic reticulum. Evidence suggests that PKA increases the permeability of calcium channels, which further 
enhances the influx of extracellular calcium. The elevated intracellular calcium levels further enhance exocytosis of insulin vesicles. The 
activation of GLP-1R also induces activation of PDX-1 transcription factor and its translocation to the nucleus, which results in the transcription 
of the preproinsulin, GLUT2 and glucokinase genes for further insulin production, glucose uptake and glucose catabolism, respectively. 
PDX-1 activation also induces the transcription of genes involved in apoptotic resistance, neogenesis and proliferation, giving GLP-1 a role 
in promoting beta-cell survival during the postprandial period in addition to enhancing insulin secretion. Studies have found that GLP-1R 
activation enhances autophagy and metabolic profiles and reduces ER stress via PKA-dependent mechanisms. This figure and information 
in its legend are adapted from1,2,46–52,56.
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potential for these therapies in dementia treatment based on 
different findings, especially in human studies12,74. Non-alcoholic 
fatty liver disease (NAFLD) and subsequent non-alcoholic 
steatohepatitis (NASH) are highly prevalent among individuals 
with T2D or obesity (or both) because of the excessive hepatic fat 
deposition associated with these diseases75,76. Studies have found 
that GLP-1R agonist treatments reduce liver pathology not 
only by promoting weight loss and improving glycaemic control 
but also by reducing alanine aminotransferase (ALT) levels, which 
was linked to the degree of weight loss induced75. The ability 
of GLP-1R agonists to reduce weight and lower ALT levels 
suggests a role for these compounds in treating NAFLD/NASH 
and reducing liver damage. A recent study found that semaglu-
tide treatment significantly reduced ALT levels in NAFLD at-risk 
patients, and histological data are awaited from an ongoing 
phase 2 trial of semaglutide in biopsy-proven NASH76. Figure 3 
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Figure 3. Summary of the reported extrapancreatic effects of glucagon-like peptide 1 (GLP-1)-based therapies (A–C) and the clinical 
implications of these findings (D). In frame C, organs that are underlined indicate that GLP-1 receptor (GLP-1R) expression is controversial/
unconfirmed, and it is not clear whether or how GLP-1 is able to mediate any direct physiological effects on them. ANP, atrial natriuretic 
peptide; CVS, cardiovascular system; eNOS, endothelial nitric oxide synthase; EPAC, exchange protein directly activated by cAMP; ERK1/2, 
extracellular signal-related kinase 1/2; MAPK, mitogen-activated protein kinase; NOD, non-obese diabetic; PI3K, phosphoinositide-3-
kinase; PKA, protein kinase A; ROS, reactive oxidative species; T1D, type 1 diabetes; T2D, type 2 diabetes; T2DM, type 2 diabetes mellitus; 
VCAM, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor. This figure and information in its legend are adapted 
from 1,2,7,12,77–98.
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summarises the findings from studies on the extrapancreatic effects 
of GLP-1-based therapies and the clinical implications of these 
findings.
A recent longitudinal study found that GLP-1–based agonist action 
may not only be an effective treatment for T2D but also prevent 
or delay disease manifestation in at-risk individuals: Liraglutide 
treatment reduced the risk of T2D manifestation in obese 
individuals and individuals who had a body mass index of more 
than 27 and had hypertension or dyslipidaemia; after 160 weeks, 
the liraglutide-treated group (n = 1472) had a smaller percentage 
of the population with diagnosed T2D (2% versus 6%) than the 
placebo-treated control group (n = 738)99. Additionally, time to 
T2D onset during the 160-week study was found to be 2.7 times 
longer in the liraglutide-treated group than the placebo control 
group. Interestingly, recent studies have also demonstrated that 
the therapeutic potential of GLP-1 action in the treatment of dis-
eases such as T2D and dementia can likely be enhanced by co- 
activation of other receptors involved in maintaining metabolic 
homeostasis. The dual GLP-1R and GIP receptor (GIPR) agonist 
treatment induced better glycaemic control and body weight 
reduction in diet-induced obesity (DIO) mice compared with 
liraglutide (GLP-1R agonist)-only-treated controls100. Co-agonism 
of GLP-1R and glucagon receptor (GR) was also shown to reduce 
body weight synergistically in rodent obesity models101. These 
co-agonists have also improved glycaemic control in monkeys 
and humans100. In a recent study, tirzepatide, a novel GLP-1R and 
GIPR co-agonist, was found to induce greater glucose control and 
weight loss in human patients with T2D than duglatide (a GLP-
1R–only agonist)102. Recently, a triple agonist for GLP-1R, GR and 
GIPR was developed and tested on DIO mice, and it was found 
that the tri-agonist lowered body weight to a greater extent than 
GLP-1R/GIPR co-agonist treatment103. The co-agonist and the 
tri-agonist were equally effective at reducing blood glucose levels 
and improving glucose tolerance without the induction of 
hypoglycaemia and this demonstrates that chronic GR agonism 
does not counteract the anti-hyperglycemic effects of GLP-1R 
and GIPR activity. Surprisingly, tri-agonist treatment lowered 
plasma insulin levels to a greater extent than the GLP-1R/GIPR co- 
agonist, indicating improved insulin sensitivity. Interestingly, no 
difference in food intake was observed between wild-type mice 
treated with the dual incretin GLP-1R/GIPR co-agonist and 
those treated with the tri-agonist despite the difference in weight 
loss and this was found to be due to significantly enhanced ATP 
expenditure in tri-agonist–treated DIO mice. The capacity of the tri- 
agonist to prevent the development of spontaneous diabetes 
compared with the dual incretin GLP-1R/GIPR co-agonist was 
also tested in mouse models of T2D. The tri-agonist treatment 
prevented the excessive weight gain in vehicle-treated mice to 
a greater degree than the GLP-1R/GIPR co-agonist and this 
difference was not due to cumulative food intake. The tri-agonist 
also protected these mice from fasting hyperglycaemia and to a 
better degree than the GLP-1R/GIPR co-agonist. Interestingly, the 
tri-agonist also significantly reduced alpha-cell infiltration into the 
core of pancreatic islets, helping to preserve the islet architecture 
observed in healthy pancreatic islets. Glycaemic improvements 
were maintained in Zucker diabetic fatty rats 3 weeks after 
treatment cessation although they had gained body weight and 
were comparable in mass to vehicle-treated controls, demon-
strating that the tri-agonist delays T2D progression in rodent 
models of spontaneous diabetes. Interestingly, this study also 
demonstrated that the effects of the tri-agonist are dependent 
on an excess of nutrient storage as weight and food intake were 
not altered in lean mice even after chronic treatment with the tri-
agonist. A recent study also found that tri-agonist treatment was 
able to ameliorate diet-induced steatohepatitis in mice77. However, 
the clinical importance of the co- and tri-agonists has yet to be 
established since the majority of the studies using these agonists 
were carried using rodent models. Some GLP1R/GIPR co-agonists 
are in clinical development for T2DM treatment.
Summary
In summary, abundant evidence has emerged over recent years 
to demonstrate that GLP-1 has multiple pancreatic effects and 
extrapancreatic targets and actions throughout the body, which 
likely play a significant role in maintaining metabolic homeos-
tasis during healthy conditions and therefore to label GLP-1 as 
just an ‘incretin hormone’ is now outdated1,2,7,12. Thus, GLP-1 has 
a much more complex and diverse physiological role than previ-
ously thought. Despite all the research that has been conducted on 
GLP-1 and its actions, the mechanisms that regulate the secretion 
of this hormone are still not fully understood, nor are the mecha-
nisms by which it exerts its actions. It is unclear whether GLP-1 is 
able to mediate its effects by an unidentified receptor, and there is 
controversy as to whether the inactive forms are able to induce 
physiological effects2,7,12. Native GLP-1 has no use therapeutically, 
but the advent of GLP-1R agonists that have much longer half-lives 
has enabled GLP-1–based actions for therapeutic uses as a viable 
option5–7. Initially, GLP-1R agonists were thought to be limited to 
T2D treatment, but it has become clear that these drugs have the 
potential to treat other diseases such as obesity, CVD, dementia 
and NAFLD2,7,12,77,103. Better understanding the mechanisms and 
signalling pathways by which acute and chronic GLP-1R 
activation both alleviates disease phenotypes and induces 
desirable physiological responses during healthy conditions 
will likely lead to the development of new therapeutic GLP-1 
action–based therapies, which improve prognosis to a greater 
extent than current therapies. Importantly, the observations that 
GLP-1–based therapies delay/prevent the manifestation of T2D99 
may enable expansion of the role of GLP-1 mimetics from 
treating diseases to delaying or preventing diseases manifesting in 
tissues susceptible to GLP-1–based action. Additionally, given the 
observations from co- and tri-agonist studies, future research 
will need to investigate what the long-term effects of synergistic 
activation of other receptors will be78,100,101,103. Finally, over recent 
years, allosteric agonists that act on sites distinct from those of 
GLP-1 and its mimetics have been developed for the GLP-1R23. 
Research is ongoing to determine whether these agonists can 
modulate GLP-1R downstream effectors to better alleviate 
pathology than current GLP-1R agonists used in the therapy. 
One advantage of these allosteric agonists is that, in contrast to 
current therapies which require injection, they can be adminis-
tered orally. Ongoing and future research into the modulation of 
GLP-1 action will likely lead to the development of new 
therapeutic strategies for an array of diseases.
Abbreviations
ALT, alanine aminotransferase; CNS, central nervous system; 
CVD, cardiovascular disease; DIO, diet-induced obesity; DPP-4, 
dipeptidyl peptidase 4; ER, endoplasmic reticulum; GIP, gastric 
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